

Company Overview

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting

Oct 11 2018, 6:55 AM EDT

Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum

Oct 8 2018, 5:00 PM EDT

Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program

Sep 17 2018, 5:30 PM EDT

Stock Overview

Symbol	NAVB
Exchange	NYSE American
Shares OS	163,620,090
Market Cap	\$46.63M
Last Price	\$0.285
52-Week	\$0.125 - \$0.68

10/12/2018 03:59 PM EDT

Investor Relations

Jed Latkin
Chief Financial and Operating Officer
T: 614-973-7490
jlatkin@navidea.com

Management Team

Jed A. Latkin

Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

Frederick Cope, Ph. D., F.A.C.N., C.N.S.

Senior Vice President and Chief Scientific Officer

William Regan

Chief Compliance Officer

Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue
Suite 240
Dublin, OH 43017

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.